Ladies and gentlemen, thank you for standing by. Welcome to the Pulmonx Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker’s presentation, there will be a question-and-answer session. Please be advised that today's conference is being recorded. I would now like to turn the conference over to Elizabeth Sparicio, Investor Relations. Please go ahead.

Good afternoon, and thank you all for participating in today's call. Joining me from Pulmonx are Steve Williamson, President and Chief Executive Officer; and Mehul Joshi, Chief Financial Officer. Earlier today, Pulmonx issued a press release announcing its financial results for the quarter ended June 30, 2024. A copy of the press release is available on Pulmonx's website. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements. All forward-looking statements, including, without limitation, those relating to our operating trends, commercial strategies and future financial performance, the timing and results of clinical trials, the impact of COVID-19 on our business and prospects for recovery, expense, management, expectations for hiring, growth in our organization, market opportunity, guidance for revenue, gross margin and operating expenses, commercial expansion and product pipeline development are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our filings with the Securities and Exchange Commission, including our annual report on Form 10-Q filed with the SEC on May 3, 2024. Also during this call, we will discuss certain non-GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are provided in the press release, which is posted on our Investor Relations website. These non-GAAP measures are not intended to be a substitute for GAAP results. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, July 31, 2024. Pulmonx disclaims any intention or obligation, except as required by law to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise. And with that, I will turn the call over to Steve.

Thank you, Elizabeth, and good afternoon, everyone. Welcome to our second quarter 2024 earnings call. Here with me today is Mehul Joshi, our Chief Financial Officer. Overall, I am pleased with our second quarter performance as we achieved a record quarter of $20.8 million in worldwide sales, representing a 21% growth over the same period of the prior year. We are encouraged by our team's continued execution of our commercial and clinical pipeline strategies as we seek to further expand patient access to Zephyr Valve and serve the 1.2 million patients with limited treatment options who stand to benefit from BLVR. The momentum we built exiting the quarter leaves us increasingly confident in our ability to deliver on the previously communicated revenue guidance of $81 million to $84 million for the full year 2024. As expected, our second quarter results were driven by the continued traction of our commercial strategy in the United States, where we achieved sales growth of 26% compared to the second quarter of 2023. As a reminder, our US commercial strategy is three-pronged. The first is training physicians of hospitals that have the potential to be high-performing Zephyr Valve centers. The second is automating patient workflows and facilitating the sharing of best practices among existing centers to optimize their Zephyr Valve programs; and third, building local awareness of the benefits of our treatment among COPD physicians and patients. Throughout the quarter, we made substantial progress in each prong of our commercial strategy. In Q2, we added 17 new accounts in the United States and ended the quarter with 267 active accounts or centers that placed a revenue-generating order in the quarter. As we continue to expand our US account base, we're engaging with the C-suite of hospital systems, which provides the opportunity to present the benefits of a Zephyr Valve treatment program to hospital administration, but then have the ability to provide needed resources for clinical support and account development. We're excited by the opportunity to serve more patients in need of our life-changing treatment with our continuously growing base of US centers. While we continue to identify potentially high-performing Zephyr Valve centers and expect to opportunistically establish new accounts, our primary focus remains on driving utilization in existing accounts. Within our existing base of Zephyr Valve centers, the team continues to establish our treatment as a more routine procedure, particularly through the sharing of best practices of our higher utilization treatment centers and the development of workflow automation tools. In June, we hosted our second annual Advanced Clinical Summit, where we had 45 dedicated professionals from 24 hospitals, passionate about advancing patient care in the field of bronchoscopic lung volume reduction. Attendees participated in a comprehensive curriculum designed to identify patients most likely to benefit from Zephyr Valve, build efficient patient pathways, and engage administration to secure necessary resources. We heard from one hospital in the southeast that attended our inaugural summit last year about their experience implementing these best practices into their own workflows. As a result, the hospital saw increased efficiency and procedural capacity, allowing them to grow their Zephyr Valve volumes from a handful of cases last year to over 40 cases in the first half of this year. This remarkable anecdote is one of many and further validates our commercial strategy and the vast opportunity we have for continued growth. During the summit, I was inspired by our growing community of partnering physicians and staff who all share a common goal of helping patients with severe emphysema and COPD breathe easier. Over the last few months, I visited treating centers across the US and abroad to connect with physicians and gain field-based insights on the success of our commercial initiatives. I was humbled by my experience witnessing the impact of our Zephyr Valve treatment on patients. My conversations with treating physicians on building efficient work streams and establishing Zephyr Valves as a routine procedure have also helped to inform the region-specific strategies we're designing today to optimize the building blocks we have in place. For example, an account in Colorado that averaged 10 cases per quarter took about six months to move patients through the treatment funnel from initial visit to implant. Together with all the key stakeholders, we helped identify bottlenecks in the process, which included a lack of procedure capacity and a clear program owner. As a result, the customer defined a new Zephyr Valve program owner and implemented process changes designed to improve workflow, such as setting up routine order sets in their EMR for all key action items. Today, the center is seeing time to treatment decrease as the number of cases per week increases. The Interventional Pulmonology team recently went to hospital administration and received two additional case slots per week with plans to ask for more as they realize the benefit of their new workflow implementation. As part of our efforts to enable cost-effective workflow efficiencies more broadly, I'm pleased to announce the upcoming pilot launch of our Lung Tracked Connect program, an automation software that enables a streamlined, efficient, and collaborative work-up process. Currently, users need to transfer CT scans onto a disk and then manually upload the scan to the StratX platform to generate a report for physician evaluation. Our new software eliminates this manual process by allowing the CT scan to be uploaded directly to the StratX platform from the hospital's tax system. Additionally, it enables the care team to track and share patient work-up status, potentially reducing time to treatment for the patient. This stands to meaningfully reduce key friction points in patient workflow and allows centers to better manage growing Zephyr Valve caseloads. We expect to initiate our pilot program in a handful of select centers in the back half of this year, and I look forward to providing further details on our progress in future calls. As we continue to share best practices, drive workflow automation, and help our customers build efficient programs that deliver a positive patient experience, we're also continuing to promote regional awareness programs for patients and community COPD physicians. These initiatives collectively enabled 20,000 patient engagements in the first half of 2024, provided peer-to-peer education to over 450 physicians, and drew broader awareness with another 6,000 physicians through digital channels like our CME program. While our primary commercial focus remains on growing our US business, we are pleased with our performance across our international markets in Q2, which resulted in OUS year-over-year revenue growth of 12%. We're continuing our work this year to adapt many of the sales tools we've developed for use in the US for use in European markets, such as operational best practice sharing, community physician engagement, and peer-to-peer education programs. The progress we've made on these initiatives was evident at our EMEA summer sales meeting in July, where I left increasingly confident in our team's ability to continue executing our commercial strategy. We anticipate the impact of our international efforts to become increasingly evident in 2025 as we focus on foundation building this year. Beyond Europe, we also continue to make progress with our expansion efforts in Asia. First, we entered into a new distribution agreement with an innovative medical supply distribution company in China. While this market represents a small portion of our business, we believe this transition to a new distributor will allow us to expand our market region in China in a more cost-effective manner. Secondly, earlier this month, I attended the 47th Annual Meeting of the Japanese Society of Respiratory Endoscopy in Osaka, where I connected with thought leaders spearheading the launch of Zephyr Valves in Japan. I'm encouraged by the positive reception our technology has received from participating centers in the early days of the post-market study and the progress our Japan team has made in driving increased awareness of Zephyr Valves. That being said, we still anticipate it will take time to grow widespread awareness of this new treatment option, and we expect the bulk of enrollment to occur in the back half of the enrollment period as we train additional sites and move the first patients through the treatment funnel. As we have said in the past, we do not expect a material revenue contribution from Japan until approximately 2026. This study marks an essential step toward broader commercialization in a new market, where we estimate approximately 100,000 patients stand to benefit from Zephyr Valves. In addition to growing our global footprint, we remain committed to our goal of expanding the number of patients that can be treated with Zephyr Valves through our AeriSeal clinical development program. We continue to make progress with our CONVERT 2 pivotal trial, a multi-center global study designed to evaluate the safety and effectiveness of the AeriSeal system in limiting collateral ventilation and severe COPD in emphysema patients. I'm excited to announce that earlier in July, I attended the first US case in the CONVERT 2 pivotal trial, where a patient was successfully treated with AeriSeal by Dr. Gerry Criner, the chair of Thoracic Medicine and Surgery at Temple University in Philadelphia, a leading AeriSeal valve center. We believe AeriSeal has the potential to expand our addressable market by approximately 20% globally. The US represents our largest share of that opportunity, and we see the first US case as a critical step forward in our journey to unlocking this important market segment. The US enrollment milestone follows the initiation of enrollment for Convert in select international centers in February of 2024. As it pertains to CONVERT 1, our European study, we look forward to the presentation of the 6-month follow-up data at the European Respiratory Society Congress in early September in Vienna. We expect the presentation will demonstrate high conversion to CV-negative status in the target lobe following AeriSeal and positive clinical outcomes following subsequent treatment with Zephyr valve. As we remain committed to further advancing long-term clinical research in our field, I'm pleased to announce that 8 abstracts have been accepted, and an additional 2 abstracts have been submitted for presentation at upcoming key scientific meetings, including ERS, the American Association of Bronchology and Interventional Pulmonology meeting, the CHEST Annual Meeting, and the World Congress of Bronchology and Interventional Pulmonology. These abstracts will cover a spectrum of new data, including the 5-year follow-up data from the LIBERATE study, reduction of severe exacerbations in patients with substantial volume reduction following Zephyr valve placement, and real-world results from our multicenter French registry. We look forward to connecting with our clinical network at these global events, which we view as a crucial component of our strategy to drive increased awareness of Zephyr valves and their clinical benefits. We are confident that the strategies we've implemented, the automation tools we are developing, and the ongoing release of new long-term clinical data will continue to drive global growth in 2025. Further, the scheduled completion of the Japanese post-approval surveillance study and the commercial launch of AeriSeal in our OUS markets will provide growth catalysts in 2026. Finally, the expected US launch of AeriSeal in 2027 rounds out a cadence of significant innovative and market-expanding launches. It is for these reasons that I believe Pulmonx is well-positioned for continued significant long-term growth. Now, I'll turn the call over to Mehul to provide a more detailed review of our second quarter results.

Thank you, Steve, and good afternoon, everyone. Total worldwide revenue for the 3 months ended June 30, 2024 was $20.8 million, a 21% increase over the prior year period and also an increase of 21% on a constant currency basis. Our strong performance was driven by continued commercial momentum and adoption of Zephyr valve therapy. US revenue in the second quarter was $13.9 million, a 26% increase over the prior year period. International revenue in the second quarter of 2024 was $6.9 million, an increase of 12% over the prior year period and also an increase of 12% on a constant currency basis. Gross margin for the second quarter of 2024 was 74%, essentially flat versus the prior year period, reflecting lower utilization, partially offset by favorable geographic mix. Total operating expenses for the second quarter of 2024 were $30.9 million, an increase of 6% over the prior year period. Operating expenses included a one-time noncash charge in R&D of $1.7 million to impair internally developed software following a strategic decision to adopt a more efficient solution. This was a result of one of our gross margin improvement initiatives that will be gross margin accretive in the long term. Excluding the one-time charge, total operating expenses were flat over the prior year period. Non-cash stock-based compensation was $5.5 million in the second quarter of 2024. Excluding stock-based compensation expense and the one-time impairment charge, total operating expenses in the second quarter of 2024 were flat over the prior year period. R&D expenses for the second quarter of 2024 were $5.6 million, a decrease of 2% over the prior year period. R&D expenses, excluding the one-time software impairment charge, were $3.9 million, down 32% versus the prior year period. The decrease was driven by lower clinical trial expenses and lower development costs. We expect R&D expense to increase from the second quarter as enrollment in our clinical trials continues to ramp. Sales, general, and administrative expenses for the second quarter of 2024 were $25.3 million, an increase of 8% over the prior year period. The increase was primarily driven by additional investment in patient awareness programs. Net loss for the second quarter of 2024 was $15.3 million or a loss of $0.39 per share as compared to a net loss of $16.2 million or a loss of $0.43 per share for the same period of the prior year. An average weighted share count of 38.9 million shares was used to determine loss per share for the second quarter of 2024. Adjusted EBITDA loss for the second quarter of 2024 was $7.6 million as compared to $10.3 million in the second quarter of 2023, reflecting a 26% improvement on a year-over-year basis. Please refer to our reconciliation of net loss to non-GAAP adjusted EBITDA for further details. We ended June 30, 2024, with $114.5 million in cash, cash equivalents, and marketable securities, a decrease of $5.9 million from March 31, 2024. Our current cash position, combined with our demonstrated ability to drive revenue growth and operating leverage beyond our existing operating plan assumptions, continues to provide confidence in our ability to become cash flow breakeven with the cash on hand. We remain laser-focused on prudent cash management and have extended the interest-only payment period for our $37 million term loan by one year. As a reminder, in October 2022, we refinanced the term loan to secure a more attractive rate and extend the maturity date to 2027, with the ability to extend the interest-only period for an additional 12 months, subject to certain conditions, which we're satisfied. The principal repayment will now begin in November 2025 with no changes to the loan interest rate or maturity date. Turning now to full year 2024 guidance. As we look ahead, we are reiterating our previously communicated fiscal year 2024 revenue, gross margin, and OpEx guidance. As a reminder, we expect to deliver a full year 2024 revenue in the range of $81 million to $84 million, representing approximately 20% growth at the midpoint. We remain confident in our guidance as we continue executing our focused commercial strategy. Our guidance continues to assume a neutral to slightly negative impact on revenue from foreign currency exchange rates. Moving down the P&L, we expect gross margin for the full year 2024 to fall within the range of 74% to 75%. Lastly, we expect operating expenses for the full year 2024 to fall between $127 million and $129 million, inclusive of approximately $25 million of noncash stock-based compensation expense. In all, we are confident in our outlook for 2024 and look forward to executing on the next stage of growth. With that, I'd like to thank you for your attention, and we will now open the call for questions.

Thank you. Our first question is from Jason Bednar with Piper Sandler. Please proceed with your question.

Good afternoon, guys. Thanks for the questions here. Nice quarter. I wanted to start with the assumptions underlying the reaffirmed guide, and just really ask on how you're thinking about the cadence of procedure volume and revenue performance here in the second half. Anything outside the typical seasonality you would anticipate for the business as you look at the typical sequential performance Q2 to Q3, same question, Q3 to Q4 or maybe just ask more directly, are you comfortable with where the street is currently sitting for the back half of the year on revenue.

Thank you for the question, Jason, and for your kind words. As we consider our guidance for the second half of the year, we've reflected on our performance in the first half, which we are pleased with. We've demonstrated solid growth. As we enter the latter part of the year, both Mehul and I haven't yet experienced the seasonal cycle. In 2022, we noticed seasonality effects both in the US and internationally. However, in 2023, it appears we have managed to navigate through the seasonal fluctuations in the US, which poses a challenging comparison for Q3. Given the differences between 2022 and 2023, we are cautious in our outlook and prefer not to make overly optimistic predictions. We are satisfied with our current performance, which is why we feel confident in reaffirming our guidance. Mehul, do you have anything to add?

No, I think you got it, Steve.

Okay. I appreciate it. That's helpful. Maybe along that same vein as we break out US versus international performance. I guess any differences in expectations on the mix that you're seeing? Is it playing out as you would have expected? And then maybe the follow-up to that is what's it going to take to get that international business back to maybe where the US is growing in that mid-20% plus range? Or should we just anticipate double digits is good enough for international? Just how you're thinking about that as we look over the next several quarters?

Sure. Regarding the international performance, it's unfolding as we anticipated. As you noted, it's not growing as rapidly as in the US. We have implemented sales process tools in our European operations. I recently attended the European sales meeting and was very impressed. The team is dedicated to executing the sales process. I left the meeting optimistic about their strategy. Looking ahead, they are focusing on patient screening, improving practice efficiencies, and providing physician education. We are also seeing a lot of physician education efforts coming from Europe. They have structured their sales plans around these initiatives, and I was very impressed with what they have developed. I believe we will start to see more of this progress by 2025. I would say that the management and the team in place are taking the right steps to increase the growth rate over time.

All right. Excellent. Just if I could squeeze in one more, just as a little bit of a check the box to your question. But seeing if there's anything we need to consider modeling-wise on the new China distribution agreement you have in place on the new distributor you're bringing on. Any inventory load-in or any accounting we need to think about as you go through that transition?

Yes. Great question, Jason. Well, I think no, nothing on the loading or accounting at all. It's a new distributor that we've brought into the mix here in our OUS strategy. I think what we believe is that going down the distributor route will enable revenue to grow significantly faster than if we were going out there and building a commercial infrastructure in China. And so as you would expect in a distributor arrangement, your gross margins are a little bit lower. But over the long term, we expect gross profit dollars and operating margins to be accretive relative to building a business there ourselves.

I think this is Steve. Jason, if I can add to that, as I consider the China market, it has a large population, as well as a significant smoking population. This suggests it could be a good market for launching our product. However, one challenge is that a considerable portion of the population is self-paying, which makes procedures like ours quite expensive. To address this, we have partnered with a distribution company that can identify the right areas and has the capacity to effectively enter this market. From our viewpoint, we expect this to generate modest revenue growth over the next couple of years, with hopes for faster growth in the future.

Got it. Helpful color. Thank you.

Thank you. Our next question comes from the line of Larry Biegelsen with Wells Fargo. Please proceed with your question. Thank you. Our next question comes from the line of Joanne Wuensch with Citi. Please proceed with your question.

Hey, good afternoon. This is Anthony on for Joanne. Congrats on the solid quarter. My first question, the 170 new US centers, that was a pretty robust step-up from last quarter. What should we be expecting for the rest of the year? And was there any particular reason why it was so strong this quarter outside of normal course of business?

Anthony, this is Steve. As we've been guiding, it's about 10 to 15 new accounts per quarter is what we expect to bring on. We were a little bit light in Q1. We were at 9, and here, we're at 17. So I think combined, we're actually a little bit above where we would expect to be right now. But there's nothing out of the ordinary there. We've had a couple of opportunities and opportunistically gone in and brought on new accounts in different areas. I will say that our focus remains on growing in the same-store sales as well. I think it's nice for us to bring on these new accounts, especially in areas where patients have to drive hours in order to get a treatment, but really, what we want to do is these centers that are set up. They've got physicians that are on board. They've got their COPD referring physicians that are already referring to them. They've built in workflow. They have coordinators and there's patient awareness and marketing activities going on in these areas. That's really where we see growth over time. And so that's a big focus for us. But obviously, we will bring on new accounts opportunistically as we need to or as we see the opportunity to do so.

Okay. That makes sense. Mehul, could you discuss the trend of margins for the second half of the year? Is 2023 a good benchmark for that? Additionally, as we consider the slight increase in operating expenses, it seems like that will be primarily focused on research and development. Can you confirm if that's the right perspective?

Sure. We guided for a gross margin of 74% to 75%. In the first half, we are at slightly over 74%, and we anticipate an increase in the second half, primarily due to higher production levels in our factory, which will help us manage utilization more effectively. Another key factor affecting gross margin is the geographical mix, which can vary and significantly impact gross margins. We have seen some fluctuations in this area both year-over-year and quarter-over-quarter, but we do expect a slight increase in gross margins for the second half of the year. Regarding expenses, particularly in R&D, as enrollment in our clinical trials begins to rise, we expect an uptick in R&D spending. There is typically a slow start when initiating a clinical trial, but the ramp-up is expected to accelerate as we progress through different phases. Therefore, we do foresee an increase in R&D spending in the second half.

Great. Thanks guys.

Thank you. Our next question comes from the line of John Young with Canaccord. Please proceed with your question.

Hey, good afternoon, guys. Thanks for taking my question and congrats on the quarter too. Maybe just convert one, can you maybe taint investors what you can to a successful trial data would be? And will you go cross Emark for AirSeal using the data? Or will you wait for convert?

So, hi John, we will present the CONVERT 1 data at ERS, which will include the six-month data. We already have the CE mark for AeriSeal, so the CONVERT 2 data will be utilized for the PMA. This is the IDE trial in the US. Once we complete enrollment, we plan to launch commercially in the EU, expected around 2026. We anticipate launching in the United States in 2027 after we go through the PMA approval process.

Okay. Thank you for that. And then it sounds like you've been really identifying friction points around just the commercial process itself, especially we talk about the software upgrade, improve the StratX workflows. What other friction points have you identified and what internal R&D work is being done? Anything around StratX or anything else in the commercial procedure that you've identified given your time in the field now?

Not really. It's a good question. We did launch a new StratX balloon that had some ease-of-use benefits for the physician, but those aren't really hold-ups to the overall growth and long-term scale of the business. I think it really comes down to the workflow and what we can do to efficiently move patients through the process. And one of the things that I'm most excited about, John, as I've gone out in the field, I think our sales process is working. It's working in both the U.S. and it's working outside the United States. Our clinical trials are progressing well in both Japan as well as CONVERT 2. Our clinical publications are strong. We've got eight different abstracts coming out. We've got two more that we're waiting to hear on. But I mean, that's a significant new clinical data that speaks to the long-term efficacy of this product. If you look internally, I think the people are bought in, our year-over-year employee turnover is slightly down year-to-date. So we're not seeing significant turnover, which I think people were originally concerned about. We've got good, strong effective patient engagement, and that continues to grow for us. And now we've got work automation software. So we've got a big untapped market. You have eager physicians that want to do more. You've got motivated patients that benefit from the procedure. We've got administrative buy-in. It's really that workflow is the key linchpin in my mind in order to really unleash a much larger volume in some of these larger centers.

Got it. Thank you again.

Thank you. Our next question comes from the line of Frank Takkinen with Lake Street Capital Markets. Please proceed with your question.

Great. Thanks for taking my questions. Maybe I'll start with the first question that was asked related to guidance. I wanted to revisit that point you made about seasonality from Q2 to Q3. Steve, I know you said it's been a little volatile in 2022 versus 2023. But kind of help us with the exact read-through we should be thinking about? I know one went up, one went down. So maybe starting there and trying to understand how we should think about Q3 of this year from a sequential standpoint if there were any one-time items in either of the previous two years that you were aware of that we can kind of glean some information from?

Yes, Frank, thanks for the question, and good to have you on the call. As we looked at 2022, we saw a decrease in both the US and OUS revenue. I think in both instances, we were pointed towards seasonality. And seasonality in this space is not only patients going on vacation, but perhaps you have doctors that go on vacation. If you have high-volume physicians that take a couple of weeks, a month off, obviously, that will affect the numbers. And so I think in 2022, that seasonality, I wasn't here, but we did see the seasonality in those revenue numbers. Moving to 2023, we were able to muscle through that seasonality in 2023 in the United States. And we didn't see the falloff that we had seen in the prior year. I think there was a lot of momentum coming in from a couple of different projects that were going on, and they were able to push through in Q3 of 2023, and now in 2024, we don't know what US sales we're going to get. We do know that we will see seasonality in Europe as the physicians take a month off in many instances. And so those are just procedures that won't take place. As we look in the US, it's kind of a mixed bag. And as we've brought on a lot of new accounts, that helps, so we dilute the impact of a small number of physicians going on vacation or not seeing patients. But overall, you also have patients that are saying, maybe I'll wait until I come back from my vacation, or they're finding different reasons to push out their procedure. Mehul, anything you want to add to that or?

No. I mean, I think the only external data point I think about is the level of travel has increased substantially this summer versus last summer. And as Steve mentioned, there are vacation schedules and things like that. So we're just uncertain of what the impact of seasonality will be in the quarter, specifically in the US. So I think we're just waiting to understand that a little bit better before we kind of think about what to do with guidance.

Okay. That's helpful. And then maybe kind of a two-parter on the pilot programs. Obviously, you heard a lot about efficiencies and workflow processes, but can you maybe call out a couple of those bottlenecks that you're seeing? Is it a consistent bottleneck that the patient is getting stopped by, or is it a case-by-case basis? And then secondly, also on the pilot programs, can you talk about maybe some of the channels you may use to enhance local awareness?

Sure. To address your question about whether the bottlenecks are consistent across the board or vary by location, I would say they differ in various places. We find that accounts that add a coordinator or navigator to manage the patient through the process see significantly better outcomes than those without. Physicians managing the workflow alone typically handle fewer cases compared to those with a navigator overseeing the process. Regarding our tools, I mentioned Lung StratX Connect, which simplifies the process for facilities by allowing navigators, coordinators, or physicians to upload CT scans directly from the PAT system without needing to deal with physical CDs. This improvement streamlines workflow and facilitates easier treatment for patients. More importantly, Lung StratX Connect enables tracking of patients throughout the treatment process. Currently, coordinators and physicians often rely on Excel spreadsheets or paper records, which is not automated. Our software enhances their ability to monitor patient progress; coordinators can log in each morning to see where their patients are in the process and organize their day based on that information. As for improving workflow, we focus on sharing best practices, which include adding coordinators, educating local physicians, and ensuring ongoing communication with referring doctors. If a referring physician does not receive updates about their patients who have been treated by an interventional pulmonologist, they may be less inclined to send more patients. However, when pulmonologists provide follow-up communication about the patient's condition, referrals tend to increase. In summary, we address workflow in three areas: sharing best practices, implementing automation through Lung StratX Connect, and enhancing efficiency for patients as we progress in future quarters.

Okay. Thanks for taking my questions.

Thank you. I show no further questions at this time. I would now like to turn the call back to Steve Williamson for closing remarks.

Thank you, Operator. To conclude, I'd like to take a moment to thank Pulmonx's employees worldwide for delivering a strong second quarter and their continued dedication to fighting every day, for every breath, so our patients don't have to. Thank you all for your time. I appreciate it.

This concludes today's conference call. Thank you for participating. You may now disconnect.